Progress and limitations in cancer gene therapy.
This is a brief discussion on the progress of gene therapy and the limitations of present-day gene therapy clinical trials based on a review of 464 human trial protocols from the U.S. National Institutes of Health (NIH) and the U.S. Federal Drug Administration (FDA). The paper also discusses an aspect of the gene therapy research of the author, who, together with colleagues, conducted the first gene therapy clinical trial in Korea in 1995.
Heo
Dae Seog
DS
Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University Medical College, Korea.
D015316:Genetic Therapy; D015793:HLA-B7 Antigen / Q000235:genetics; D006801:Humans; D016246:Lymphocytes, Tumor-Infiltrating / Q000378:metabolism; D009369:Neoplasms / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D009857:Oncogenes; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics
D015793:HLA-B7 Antigen; D014409:Tumor Necrosis Factor-alpha